Takeuchi Issei, Onaka Haruhiko, Makino Kimiko
Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda, Chiba 278-8510, Japan.
Center for Drug Delivery Research, Tokyo University of Science, 2641, Yamazaki, Noda, Chiba 278-8510, Japan.
Biomed Mater Eng. 2018;29(2):205-215. doi: 10.3233/BME-171723.
Recently, polyethylene glycol (PEG) modified gold nanoparticles have been studied to maintaining long-term stability in biological fluids. Its biodistribution was also reported, however, comparison of bare gold nanoparticles and PEGylated gold nanoparticles with equal particle size is not sufficient.
We prepared bare gold nanoparticles and PEGylated gold nanoparticles with diameters of 20-30-nm or 50-nm to avoid the influence of particle diameter, and studied their biodistribution in the mouse.
Gold concentrations in brain, heart, lungs, liver, stomach, pancreas, spleen, kidneys, blood, urine, and feces were measured at 0.5, 1, 2, 3, 6, 12, 18, 24, and 48 h after administration of gold nanoparticles using inductively coupled plasma atomic emission spectrometry.
At 48 h after intravenous administration, accumulation in the liver and spleen was significantly reduced by PEGylation, and the gold amounts of PEGylated gold nanoparticles with diameters of 20-30 nm and 50-nm in the brain were 3.6 times and 2.7 times higher than those of bare gold nanoparticles, respectively.
These results indicated that the usefulness of PEGylated gold nanoparticles with small particle size for a drug carrier.
最近，聚乙二醇（PEG）修饰的金纳米颗粒已被研究用于在生物流体中维持长期稳定性。其生物分布也有报道，然而，对具有相同粒径的裸金纳米颗粒和聚乙二醇化金纳米颗粒的比较并不充分。
我们制备了直径为20 - 30纳米或50纳米的裸金纳米颗粒和聚乙二醇化金纳米颗粒，以避免粒径的影响，并研究它们在小鼠体内的生物分布。
在给予金纳米颗粒后的0.5、1、2、3、6、12、18、24和48小时，使用电感耦合等离子体原子发射光谱法测量脑、心脏、肺、肝、胃、胰腺、脾、肾、血液、尿液和粪便中的金浓度。
静脉注射后48小时，聚乙二醇化显著降低了肝脏和脾脏中的蓄积，直径为20 - 30纳米和50纳米的聚乙二醇化金纳米颗粒在脑中的金含量分别比裸金纳米颗粒高3.6倍和2.7倍。
这些结果表明小粒径聚乙二醇化金纳米颗粒作为药物载体的实用性。
